Details der Publikation - Pembrolizumab (CinnaGen Co, Iran) in COVID-19

Medienart:	Klinische Studie

Erscheinungsjahr:	2020
Erschienen:	2020

Enthalten in:	WHO International Clinical Trials Registry Platform - (2020) vom: 15. Juni Zur Gesamtaufnahme - year:2020

Sprache:	Unbestimmt

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: COVID-19. COVID-19;U07.1 Recruitment Status: Recruiting Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2020-05-27, Last updated: 2022-11-24

ICTRP ID:	IRCT20150303021315N19

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO005068312


LEADER	01000caa a22002652 4500
001	WHO005068312
003	DE-627
005	20230425165737.0
007	cr uuu---uuuuu
008	210507s2020 xx \|\|\|\|\|o 00\| \|\|und c
035			\|a (DE-627)WHO005068312
035			\|a (UBBS_Klinische_Studien_WHO)IRCT20150303021315N19
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a und
245	1	0	\|a Pembrolizumab (CinnaGen Co, Iran) in COVID-19 \|b The evaluation of safety and efficacy of Pembrolizumab (CinnaGen Co, Iran) in patients with COVID-19
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2020-05-27, Last updated: 2022-11-24
650		4	\|a Medical Condition: COVID-19. COVID-19;U07.1
650		4	\|a Study Type: Interventional
650		4	\|a Recruitment Status: Recruiting
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2020) vom: 15. Juni
773	1	8	\|g year:2020 \|g day:15 \|g month:06
856	4	0	\|u http://en.irct.ir/trial/47335 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2020 \|b 15 \|c 06